Drug intelligence / Profile preview

YH33619

Development stage: Preclinical
Lead developer: Gilead Sciences
Modality: Small Molecules
Administration: Oral, Injection

Overview

YH33619 is a preclinical-stage small molecule new chemical entity (NCE) being developed by Yuhan Corporation and its US-based subsidiary, AB Pharmaceuticals. The drug is currently under investigation for the treatment of metabolic diseases and fibrosis. While the specific molecular target and mechanism of action remain undisclosed by the developer, the candidate is positioned within Yuhan's pipeline to address high-need areas such as metabolic dysfunction-associated steatohepatitis (MASH) and associated chronic fibrotic conditions.

Beyond the preview

Go deeper on YH33619.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on YH33619.

Explore the full profile